Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;37 Suppl 1(Suppl 1):73-80.
doi: 10.1111/liv.13324.

From HCV To HBV Cure

Raymond F Schinazi  1 , Tarik Asselah  2
Affiliations
Review

From HCV To HBV Cure

Raymond F Schinazi et al. Liver Int. 2017 Jan.

Abstract

Approximately 170 million people are chronically infected with HCV and 350 million are chronically infected with HBV worldwide. It is estimated that more than one million patients die from complications related to chronic viral hepatitis, mainly HCC which is one of the most frequent cancers in many countries, especially Africa, the Middle East and Asia. HCV drug development has been impressive, and this revolution led to several direct-acting antiviral agents achieving an HCV cure after only 6-12 weeks. This progress could theorically lead to HCV global elimination making HCV and its consequences a rarity. HBV research and development programs can learn from the HCV experience, to achieve an HBV functional or sterilizing cure. This review will summarize key steps which have been realized for an HCV cure, and discuss the next steps to achieve for an HCV elimination. And also, how this HCV revolution has inspired scientists and clinicians to achieve the same for HBV.

Keywords: HBV cure; HCV elimination; capsid inhibitors; cccDNA; direct-acting antivirals.

PubMed Disclaimer

Conflict of interest statement

Raymond Schinazi is the founder and major shareholder of Cocrystal Pharma, Inc. Tarik Asselah is a speaker and investigator for Abbvie, BMS, Boehringer-Ingelheim, Tibotec, Janssen, Gilead, Roche and MSD

References

    1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62. - PubMed
    1. Lohmann V, Korner F, Koch J, et al. Replication of sub- genomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–3. - PubMed
    1. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science. 2000;290:1972–4. - PubMed
    1. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996;87:343–55. - PubMed
    1. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol. 1997;4:463–7. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources